Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review
  • Published:

Angiotensin inhibition and malignancies: a review

Journal of Human Hypertension volume 23, pages 623–635 (2009)Cite this article

Abstract

After an early report that patients treated with angiotensin-converting enzyme (ACE) inhibitors had a lower than expected incidence of cancers, there was a large number of publications investigating the possible pathophysiological mechanism mediating this effect, as well as population studies comparing the incidence of cancers in patients treated with agents inhibiting the renin–angiotensin system with their incidence in the general population. Several mechanisms are proposed to explain a potential anti-tumour activity of such agents in vitro in experimental animal models. However, the population studies are mostly inconclusive, although they do suggest a possible interaction between ACE genotypes and susceptibility to altered behaviour of certain tumours.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Lever AF, Hole DJ, Gillis CR, McCallum IR, McInnes GT, MacKinnon PL et al. Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? Lancet 1998; 352: 179–184.

    Article  CAS  PubMed  Google Scholar 

  2. Deshayes F, Nahmias C . Angiotensin receptors: a new role in cancer? Trends Endocrinol Metab 2005; 16: 293–299.

    Article  CAS  PubMed  Google Scholar 

  3. Folkman J, Watson K, Ingber D, Hanahan D . Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 1989; 339: 58–61.

    Article  CAS  PubMed  Google Scholar 

  4. Escobar E, Rodriguez-Reyna TS, Arrieta O, Sotelo J . Angiotensin II, cell proliferation and angiogenesis regulator: biologic and therapeutic implications in cancer. Curr Vasc Pharmacol 2004; 2: 385–399.

    Article  CAS  PubMed  Google Scholar 

  5. Sugimoto M, Furuta T, Shirai N, Ikuma M, Sugimura H, Hishida A . Influences of chymase and angiotensin I-converting enzyme gene polymorphisms on gastric cancer risks in Japan. Cancer Epidemiol Biomarkers Prev 2006; 15: 1929–1934.

    Article  CAS  PubMed  Google Scholar 

  6. Molteni A, Ward WF, Ts’ao CH, Taylor J, Small Jr W, Brizio-Molteni L et al. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr Pharm Des 2003; 9: 751–761.

    Article  CAS  PubMed  Google Scholar 

  7. Ignjacev-Lazich I, Kintsurashvili E, Johns C, Vitseva O, Duka A, Shenouda S et al. Angiotensin-converting enzyme regulates bradykinin receptor gene expression. Am J Physiol Heart Circ Physiol 2005; 289: H1814–H1820.

    Article  CAS  PubMed  Google Scholar 

  8. Lindberg H, Nielsen D, Jensen BV, Eriksen J, Skovsgaard T . Angiotensin converting enzyme inhibitors for cancer treatment? Acta Oncol 2004; 43: 142–152.

    Article  CAS  PubMed  Google Scholar 

  9. Castellon R, Hamdi HK . Demystifying the ACE polymorphism: from genetics to biology. Curr Pharm Des 2007; 13: 1191–1198.

    Article  CAS  PubMed  Google Scholar 

  10. Tahmasebi M, Barker S, Puddefoot JR, Vinson JP . Localisation of renin-angiotensin system (RAS) components in breast. Br J Cancer 2006; 95: 67–74.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. De Paepe B, Verstraeten VL, De Potter CR, Vakaet LA, Bullock GR . Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma. Histochem Cell Biol 2001; 116: 247–254.

    Article  CAS  PubMed  Google Scholar 

  12. De Paepe B, Verstraeten VM, De Potter CR, Bullock GR . Increased angiotensin II type-2 receptor density in hyperplasia, DCIS and invasive carcinoma of the breast is paralleled with increased iNOS expression. Histochem Cell Biol 2002; 117: 13–19.

    Article  CAS  PubMed  Google Scholar 

  13. Herr D, Rodewald M, Fraser HM, Hack G, Konrad R, Kreienberg R et al. Potential role of renin-angiotensin-system for tumor angiogenesis in receptor negative breast cancer. Gynecol Oncol 2008; 109: 418–425.

    Article  CAS  PubMed  Google Scholar 

  14. Small Jr W, Molteni A, Kim YT, Taylor JM, Chen Z, Ward WF . Captopril modulates hormone receptor concentration and inhibits proliferation of human mammary ductal carcinoma cells in culture. Breast Cancer Res Treat 1997; 44: 217–224.

    Article  CAS  PubMed  Google Scholar 

  15. Chochieva AR, Bolieva LZ, Dzhioev FK . New approaches to the drug prophylaxis of mammary tumor: evaluation of the prophylactic effect of lovastatin and captopril in rats with experimental mammary gland tumors. Eksp Klin Farmakol 2008; 71: 43–45 (in Russian).

    CAS  PubMed  Google Scholar 

  16. Isobe A, Takeda T, Sakata M, Miyake A, Yamamoto T, Minekawa R et al. Dual repressive effect of angiotensin II-type 1 receptor blocker telmisartan on angiotensin II-induced and estradiol-induced uterine leiomyoma cell proliferation. Hum Reprod 2008; 23: 440–446.

    Article  CAS  PubMed  Google Scholar 

  17. Suganuma T, Ino K, Shibata K, Kajiyama H, Nagasaka T, Mizutani S et al. Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination. Clin Cancer Res 2005; 11: 2686–2694.

    Article  CAS  PubMed  Google Scholar 

  18. Ishiguro H, Ishiguro Y, Kubota Y, Uemura H . Regulation of prostate cancer cell growth and PSA expression by angiotensin II receptor blocker with peroxisome proliferator-activated receptor gamma ligand like action. Prostate 2007; 67: 924–932.

    Article  CAS  PubMed  Google Scholar 

  19. Uemura H, Ishiguro H, Kubota Y . Pharmacology and new perspectives of angiotensin II receptor blocker in prostate cancer treatment. Int J Urol 2008; 15: 19–26.

    Article  CAS  PubMed  Google Scholar 

  20. Uemura H, Hasumi H, Ishiguro H, Teranishi J, Miyoshi Y, Kubota Y . Renin-angiotensin system is an important factor in hormone refractory prostate cancer. Prostate 2006; 66: 822–830.

    Article  CAS  PubMed  Google Scholar 

  21. Volpert OV, Ward WF, Lingen MW, Chesler L, Solt DB, Johnson MD et al. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J Clin Invest 1996; 98: 671–679.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Tsujinoue H, Nakatani T et al. Inhibition of renin-angiotensin system attenuates liver enzyme-altered preneoplastic lesions and fibrosis development in rats. J Hepatol 2002; 37: 22–30.

    Article  CAS  PubMed  Google Scholar 

  23. Yoshiji H, Kuriyama S, Kawata M, Yoshii J, Ikenaka Y, Noguchi R et al. The angiotensin-I-converting enzyme inhibitor perindopril suppresses tumor growth and angiogenesis: possible role of the vascular endothelial growth factor. Clin Cancer Res 2001; 7: 1073–1078.

    CAS  PubMed  Google Scholar 

  24. Yoshiji H, Yoshii J, Ikenaka Y, Noguchi R, Yanase K, Tsujinoue H et al. Suppression of the renin-angiotensin system attenuates vascular endothelial growth factor-mediated tumor development and angiogenesis in murine hepatocellular carcinoma cells. Int J Oncol 2002; 20: 1227–1231.

    CAS  PubMed  Google Scholar 

  25. Yoshiji H, Kuriyama S, Fukui H . Angiotensin-I-converting enzyme inhibitors may be an alternative anti-angiogenic strategy in the treatment of liver fibrosis and hepatocellular carcinoma. Possible role of vascular endothelial growth factor. Tumour Biol 2002; 23: 348–356.

    Article  CAS  PubMed  Google Scholar 

  26. Yoshiji H, Kuriyama S, Noguchi R, Fukui H . Angiotensin-I converting enzyme inhibitors as potential anti-angiogenic agents for cancer therapy. Curr Cancer Drug Targets 2004; 4: 555–567.

    Article  CAS  PubMed  Google Scholar 

  27. Noguchi R, Yoshiji H, Kuriyama S, Yoshii J, Ikenaka Y, Yanase K et al. Combination of interferon-beta and the angiotensin-converting enzyme inhibitor, perindopril, attenuates murine hepatocellular carcinoma development and angiogenesis. Clin Cancer Res 2003; 9 (16 Part 1): 6038–6045.

    CAS  PubMed  Google Scholar 

  28. Yanase K, Yoshiji H, Ikenaka Y, Noguchi R, Kitade M, Kaji K et al. Synergistic inhibition of hepatocellular carcinoma growth and hepatocarcinogenesis by combination of 5-fluorouracil and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2007; 17: 441–446.

    CAS  PubMed  Google Scholar 

  29. Yoshiji H, Kuriyama S, Noguchi R, Yoshii J, Ikenaka Y, Yanase K et al. Amelioration of carcinogenesis and tumor growth in the rat liver by combination of vitamin K2 and angiotensin-converting enzyme inhibitor via anti-angiogenic activities. Oncol Rep 2006; 15: 155–159.

    CAS  PubMed  Google Scholar 

  30. Yoshiji H, Noguchi R, Yamazaki M, Ikenaka Y, Sawai M, Ishikawa M et al. Combined treatment of vitamin K2 and angiotensin-converting enzyme inhibitor ameliorates hepatic dysplastic nodule in a patient with liver cirrhosis. World J Gastroenterol 2007; 13: 3259–3261.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Hii SI, Nicol DL, Gotley DC, Thompson LC, Green MK, Jonsson JR . Captopril inhibits tumour growth in a xenograft model of human renal cell carcinoma. Br J Cancer 1998; 77: 880–883.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Miyajima A, Kosaka T, Asano T, Asano T, Seta K, Kawai T et al. Angiotensin II type I antagonist prevents pulmonary metastasis of murine renal cancer by inhibiting tumor angiogenesis. Cancer Res 2002; 62: 4176–4179.

    CAS  PubMed  Google Scholar 

  33. Reddy MK, Baskaran K, Molteni A . Inhibitors of angiotensin-converting enzyme modulate mitosis and gene expression in pancreatic cancer cells. Proc Soc Exp Biol Med 1995; 210: 221–226.

    Article  CAS  PubMed  Google Scholar 

  34. Ohta T, Amaya K, Yi S, Kitagawa H, Kayahara M, Ninomiya I et al. Angiotensin converting enzyme-independent, local angiotensin II-generation in human pancreatic ductal cancer tissues. Int J Oncol 2003; 23: 593–598.

    CAS  PubMed  Google Scholar 

  35. Arafat HA, Gong Q, Chipitsyna G, Rizvi A, Saa CT, Yeo CJ . Antihypertensives as novel antineoplastics: angiotensin-I-converting enzyme inhibitors and angiotensin II type 1 receptor blockers in pancreatic ductal adenocarcinoma. J Am Coll Surg 2007; 204: 996–1005.

    Article  PubMed  Google Scholar 

  36. Kucerova D, Zelezna B, Sloncova E, Sovova V . Angiotensin II receptors on colorectal carcinoma cells. Int J Mol Med 1998; 2: 593–595.

    CAS  PubMed  Google Scholar 

  37. Takagi T, Nakano Y, Takekoshi S, Inagami T, Tamura M . Hemizygous mice for the angiotensin II type 2 receptor gene have attenuated susceptibility to azoxymethane-induced colon tumorigenesis. Carcinogenesis 2002; 23: 1235–1241.

    Article  CAS  PubMed  Google Scholar 

  38. Attoub S, Gaben AM, AL-Salam S, Al Sultan MA, John A, Nicholls MG et al. Captopril as a potential inhibitor of lung tumor growth and metastasis. Ann NY Acad Sci 2008; 1138: 65–72.

    Article  CAS  PubMed  Google Scholar 

  39. Kowalski J, Belowski D, Madej A, Herman ZS . Effects of thiorphan, bestatin and captopril on the Lewis lung carcinoma metastases in mice. Pol J Pharmacol 1995; 47: 423–427.

    CAS  PubMed  Google Scholar 

  40. Prontera C, Mariani B, Rossi C, Poggi A, Rotilio D . Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int J Cancer 1999; 81: 761–766.

    Article  CAS  PubMed  Google Scholar 

  41. Kowalski J, Herman ZS . Captopril augments antitumor activity of cyclophosphamide in mice. Pol J Pharmacol 1996; 48: 281–285.

    Article  CAS  PubMed  Google Scholar 

  42. Egami K, Murohara T, Shimada T, Sasaki K, Shintani S, Sugaya T et al. Role of host angiotensin II type 1 receptor in tumor angiogenesis and growth. J Clin Invest 2003; 112: 67–75.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. de Groot-Besseling RR, Ruers TJ, van Kraats A, Poelen GJ, Ruiter DJ, de Waal RM et al. Anti-tumor activity of a combination of plasminogen activator and captopril in a human melanoma xenograft model. Int J Cancer 2004; 112: 329–334.

    Article  CAS  PubMed  Google Scholar 

  44. Juillerat-Jeanneret L, Celerier J, Chapuis Bernasconi C, Nguyen G, Wostl W, Maerki HP et al. Renin and angiotensinogen expression and functions in growth and apoptosis of human glioblastoma. Br J Cancer 2004; 90: 1059–1068.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  45. Fogarty DJ, Sánchez-Gómez MV, Matute C . Multiple angiotensin receptor subtypes in normal and tumor astrocytes in vitro. Glia 2002; 39: 304–313.

    Article  PubMed  Google Scholar 

  46. Nakagawa T, Kubota T, Kabuto M, Kodera T . Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer Res 1995; 15 (5B): 1985–1989.

    CAS  PubMed  Google Scholar 

  47. Arrieta O, Guevara P, Escobar E, García-Navarrete R, Pineda B, Sotelo J . Blockage of angiotensin II type I receptor decreases the synthesis of growth factors and induces apoptosis in C6 cultured cells and C6 rat glioma. Br J Cancer 2005; 92: 1247–1252.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  48. Chen L, Re RN, Prakash O, Mondal D . Angiotensin-converting enzyme inhibition reduces neuroblastoma cell growth rate. Proc Soc Exp Biol Med 1991; 196: 280–283.

    Article  CAS  PubMed  Google Scholar 

  49. Fujita M, Hayashi I, Yamashina S, Itoman M, Majima M . Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis. Biochem Biophys Res Commun 2002; 294: 441–447.

    Article  CAS  PubMed  Google Scholar 

  50. Fujita M, Hayashi I, Yamashina S, Fukamizu A, Itoman M, Majima M . Angiotensin type 1a receptor signaling-dependent induction of vascular endothelial growth factor in stroma is relevant to tumor-associated angiogenesis and tumor growth. Carcinogenesis 2005; 26: 271–279.

    Article  CAS  PubMed  Google Scholar 

  51. Ward WF, Molteni A, Ts’ao C, Hinz JM . The effect of Captopril on benign and malignant reactions in irradiated rat skin. Br J Radiol 1990; 63: 349–534.

    Article  CAS  PubMed  Google Scholar 

  52. Takeda H, Kondo S . Differences between squamous cell carcinoma and keratoacanthoma in angiotensin type-1 receptor expression. Am J Pathol 2001; 158: 1633–1637.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  53. Takeda H, Katagata Y, Kondo S . Immunohistochemical study of angiotensin receptors in human anagen hair follicles and basal cell carcinoma. Br J Dermatol 2002; 147: 276–280.

    Article  CAS  PubMed  Google Scholar 

  54. Meier CR, Derby LE, Jick SS, Jick H . Angiotensin-converting enzyme inhibitors, calcium channel blockers, and breast cancer. Arch Intern Med 2000; 160: 349–353.

    Article  CAS  PubMed  Google Scholar 

  55. Stahl M, Bulpitt CJ, Palmer AJ, Beevers DG, Coles EC, Webster J . Calcium channel blockers, ACE inhibitors, and the risk of cancer in hypertensive patients: a report from the Department of Human Health Hypertension Care Computing Project (DHCCP). J Hum Hypertens 2000; 14: 299–304.

    Article  CAS  PubMed  Google Scholar 

  56. Friis S, Sørensen HT, Mellemkjaer L, McLaughlin JK, Nielsen GL, Blot WJ et al. Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. Cancer 2001; 92: 2462–2470.

    Article  CAS  PubMed  Google Scholar 

  57. Lindholm LH, Anderson H, Ekbom T, Hansson L, Lanke J, Dahlöf B et al. Relation between drug treatment and cancer in hypertensives in the Swedish Trial in Old Patients with Hypertension 2: a 5-year, prospective, randomised, controlled trial. Lancet 2001; 358: 539–544.

    Article  CAS  PubMed  Google Scholar 

  58. Li CI, Malone KE, Weiss NS, Boudreau DM, Cushing-Haugen KL, Daling JR . Relation between use of antihypertensive medications and risk of breast carcinoma among women ages 65–79 years. Cancer 2003; 98: 1504–1513.

    Article  PubMed  Google Scholar 

  59. van der Knaap R, Siemes C, Coebergh JW, van Duijn CM, Hofman A, Stricker BH . Renin-angiotensin system inhibitors, angiotensin I-converting enzyme gene insertion/deletion polymorphism, and cancer: the Rotterdam Study. Cancer 2008; 112: 748–757.

    Article  PubMed  Google Scholar 

  60. Koh WP, Yuan JM, Sun CL, van den Berg D, Seow A, Lee HP et al. Angiotensin I-converting enzyme (ACE) gene polymorphism and breast cancer risk among Chinese women in Singapore. Cancer Res 2003; 63: 573–578.

    CAS  PubMed  Google Scholar 

  61. Koh WP, Yuan JM, van den Berg D, Lee HP, Yu MC . Polymorphisms in angiotensin II type 1 receptor and angiotensin I-converting enzyme genes and breast cancer risk among Chinese women in Singapore. Carcinogenesis 2005; 26: 459–464.

    Article  CAS  PubMed  Google Scholar 

  62. González-Zuloeta Ladd AM, Arias Vásquez A, Sayed-Tabatabaei FA, Coebergh JW, Hofman A, Njajou O et al. Angiotensin-converting enzyme gene insertion/deletion polymorphism and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2005; 14: 2143–2146.

    Article  PubMed  Google Scholar 

  63. Yaren A, Turgut S, Kursunluoglu R, Oztop I, Turgut G, Degirmencioglu S et al. Insertion/deletion polymorphism of the angiotensin I-converting enzyme gene in patients with breast cancer and effects on prognostic factors. J Investig Med 2007; 55: 255–261.

    Article  CAS  PubMed  Google Scholar 

  64. Kikkawa F, Mizuno M, Shibata K, Kajiyama H, Morita T, Ino K et al. Activation of invasiveness of cervical carcinoma cells by angiotensin II. Am J Obstet Gynecol 2004; 190: 1258–1263.

    Article  CAS  PubMed  Google Scholar 

  65. Freitas-Silva M, Pereira D, Coelho C, Bicho M, Lopes C, Medeiros R . Angiotensin I-converting enzyme gene insertion/deletion polymorphism and endometrial human cancer in normotensive and hypertensive women. Cancer Genet Cytogenet 2004; 155: 42–46.

    Article  CAS  PubMed  Google Scholar 

  66. Hsieh YY, Lee CC, Chang CC, Wang YK, Yeh LS, Lin CS . Angiotensin I-converting enzyme insertion-related genotypes and allele are associated with higher susceptibility of endometriosis and leiomyoma. Mol Reprod Dev 2007; 74: 808–814.

    Article  CAS  PubMed  Google Scholar 

  67. Ronquist G, Rodriguez LA, Ruigómez A, Johansson S, Wallander MA, Frithz G et al. Association between captopril, other antihypertensive drugs and risk of prostate cancer. Prostate 2004; 58: 50–56.

    Article  CAS  PubMed  Google Scholar 

  68. Medeiros R, Vasconcelos A, Costa S, Pinto D, Lobo F, Morais A et al. Linkage of angiotensin I-converting enzyme gene insertion/deletion polymorphism to the progression of human prostate cancer. J Pathol 2004; 202: 330–335.

    Article  CAS  PubMed  Google Scholar 

  69. Yigit B, Bozkurt N, Narter F, Yilmaz H, Yucebas E, Isbir T . Effects of ACE I/D polymorphism on prostate cancer risk, tumor grade and metastasis. Anticancer Res 2007; 27: 933–936.

    CAS  PubMed  Google Scholar 

  70. Sjöberg T, Garcia Rodriguez LA, Lindblad M . Angiotensin-converting enzyme inhibitors and risk of esophageal and gastric cancer: a nested case-control study. Clin Gastroenterol Hepatol 2007; 5: 1160–1166.e1.

    Article  PubMed  Google Scholar 

  71. Khurana V, Kyanam K, Caldito G . Angiotensin converting enzyme inhibitors reduce the incidence of esophageal cancer: a study of half a million US veterans. Gastroenterology 2006; 130, Issue 4, Supplement 2, M 2098 A 413.

  72. Khurana V, Sheth A, Caldito G, Barkin JS . Angiotensin converting enzyme inhibitors reduce the incidence of pancreatic cancer: a study of half a million US veterans. Gastroenterology 2006; 130, Issue 4, Supplement 2, M 2163 A-425–426.

  73. Khurana V, Bejjanki HR, Caldito G . Angiotensin converting enzyme inhibitors reduce the incidence of colon cancer: a study of half a million US veterans. Gastroenterology 2006; 130, Issue 4, Supplement 2, S 1222 A 180.

  74. Ebert MP, Lendeckel U, Westphal S, Dierkes J, Glas J, Folwaczny C et al. The angiotensin I-converting enzyme gene insertion/deletion polymorphism is linked to early gastric cancer. Cancer Epidemiol Biomarkers Prev 2005; 14: 2987–2989.

    Article  CAS  PubMed  Google Scholar 

  75. Goto Y, Ando T, Nishio K, Ishida Y, Kawai S, Goto H et al. The ACE gene polymorphism is associated with the incidence of gastric cancer among H. pylori seropositive subjects with atrophic gastritis. Asian Pac J Cancer Prev 2005; 6: 464–467.

    PubMed  Google Scholar 

  76. Röcken C, Lendeckel U, Dierkes J, Westphal S, Carl-McGrath S, Peters B et al. The number of lymph node metastases in gastric cancer correlates with the angiotensin I-converting enzyme gene insertion/deletion polymorphism. Clin Cancer Res 2005; 11: 2526–2530.

    Article  PubMed  Google Scholar 

  77. Carl-McGrath S, Ebert MP, Lendeckel U, Röcken C . Expression of the local angiotensin II system in gastric cancer may facilitate lymphatic invasion and nodal spread. Cancer Biol Ther 2007; 6 (8): 1218–1226.

    Article  CAS  PubMed  Google Scholar 

  78. Neo JH, Malcontenti-Wilson C, Muralidharan V, Christophi C . Effect of ACE inhibitors and angiotensin II receptor antagonists in a mouse model of colorectal cancer liver metastases. J Gastroenterol Hepatol 2007; 22: 577–584.

    Article  CAS  PubMed  Google Scholar 

  79. Christian JB, Lapane KL, Hume AL, Eaton CB, Weinstock MA, VATTC Trial. Association of ACE inhibitors and angiotensin receptor blockers with keratinocyte cancer prevention in the randomized VATTC trial. J Natl Cancer Inst 2008; 100: 1223–1232.

    Article  CAS  PubMed  Google Scholar 

  80. Stanojkovic TP, Zizak Z, Mihailovic-Stanojevic N, Petrovic T, Juranic Z . Inhibition of proliferation on some neoplastic cell lines-act of carvedilol and captopril. J Exp Clin Cancer Res 2005; 24: 387–395.

    CAS  PubMed  Google Scholar 

  81. Heffelfinger SC . The renin angiotensin system in the regulation of angiogenesis. Curr Pharm Des 2007; 13: 1215–1229.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Physiology and Pharmacology, Hypertension Research Unit, Sackler School of Medicine, Tel-Aviv University, Tel-Aviv, Israel

    T Rosenthal

  2. Hypertension and Atherosclerosis Section, Boston University School of Medicine, Boston, MA, USA

    I Gavras

Authors
  1. T Rosenthal
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. I Gavras
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to T Rosenthal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Rosenthal, T., Gavras, I. Angiotensin inhibition and malignancies: a review. J Hum Hypertens 23, 623–635 (2009). https://doi.org/10.1038/jhh.2009.21

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/jhh.2009.21

Keywords

This article is cited by

Search

Advanced search

Quick links